Johnson & Johnson (JNJ) Price & Analysis

Compare

27,598 Followers

JNJ Stock Chart & Stats

$207.35

-$4.08(-2.79%)

At close: Jan 08 4:00 PM EST

$207.35

-$4.08(-2.79%)

Day’s Range― - ―

52-Week Range$140.68 - $215.19

Previous CloseN/A

Volume3.80M

Average Volume (3M)7.16M

Market Cap

$492.24B

Enterprise Value$429.24B

Total Cash (Recent Filing)$18.56B

Total Debt (Recent Filing)$45.80B

Price to Earnings (P/E)19.7

Beta0.11

Next Earnings

Jan 21, 2026

EPS Estimate

2.51

Next Dividend Ex-DateN/A

Dividend Yield2.5%

Share Statistics

EPS (TTM)2.80

Shares Outstanding2,409,295,200

10 Day Avg. Volume3,991,352

30 Day Avg. Volume7,160,500

Financial Highlights & Ratios

PEG Ratio-0.42

Price to Book (P/B)4.83

Price to Sales (P/S)3.88

P/FCF Ratio17.39

Enterprise Value/Market Cap0.87

Enterprise Value/Revenue4.66

Enterprise Value/Gross Profit6.84

Enterprise Value/Ebitda10.85

Forecast

1Y Price Target

$219.05

Price Target Upside5.64% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering19

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Business StrategyJNJ announced a planned separation of its ortho business, which should boost the company's outer year growth.

Financial PerformanceJNJ shares have continued their impressive performance, with the stock up approximately 30% since July 1.

Product DevelopmentTecvayli + Darzalex demonstrated significantly improved progression-free survival and overall response rates in the MajesTEC-3 trial, indicating strong efficacy in the treatment setting.

Bears Say

Pipeline LimitationsOpportunities for further re-rate are constrained by limited pipeline catalysts and lack of conviction on upward estimate revisions.

Tax ImplicationsJNJ now expects a higher tax rate of 17.5%-18.0% due to the OBBBA.

Valuation ConcernsThe company's valuation is considered above-average, even when factoring in the higher multiple for the MedTech business, implying it is fairly valued.

Johnson & Johnson News

LLY, JNJ, PFE: Big Pharma’s 2025 Comeback Is Bigger Than the Obesity Craze

The race for obesity-drug market share was one key highlight for Big Pharma in 2025. However, data indicate...

3h ago

AZN

JNJ

Johnson & Johnson submits Ottava Robotic Surgical System to the FDA

Johnson & Johnson announced that the company has submitted the Ottava Robotic Surgical System to the FDA in...

19h ago

JNJ

Apogee Therapeutics Stock (APGE) Plunges despite ‘Positive’ Asthma Drug Trial

Shares in biotech firm Apogee Therapeutics ($APGE) sank about 5% early Tuesday despite reporting “positive” results from its...

2d ago

JNJ

APGE

Johnson & Johnson announces ‘positive results from Phase 2b JASMINE study

Johnson & Johnson announced positive topline results from the Phase 2b JASMINE study of adults living with systemic...

2d ago

JNJ

Kennedy scales back number of vaccines recommended for children, NYT says

Federal health officials on Monday announced dramatic revisions to the slate of vaccines recommended for American children, reducing...

3d ago

AZN

GSK

3 Best ETFs to Invest In, According to AI Analyst, 12/31/2025

The ETF market offers endless choices. However, that abundance often leaves investors unsure where to start. TipRanks’ ETF...

8d ago

HDV

JNJ

Johnson & Johnson price target raised to $217 from $197 at Barclays

Barclays raised the firm’s price target on Johnson & Johnson to $217 from $197 and keeps an Equal...

9d ago

JNJ

J&J failure likely a ‘clearing event’ for Apogee Therapeutics, says BTIG

After Johnson & Johnson (JNJ) recently reported that the Phase 2b DUPLEX-AD proof-of-concept study of JNJ-95475939 for the...

9d ago

JNJ

APGE

3 Best ETFs to Invest In, According to AI Analyst, 12/23/2025

With thousands of ETFs competing for attention, spotting the real winners can be challenging. TipRanks’ ETF AI Analyst...

16d ago

JNJ

MGC

Morning Movers: Novo Nordisk gains after Wegovy pill approved

Stock futures edged lower after delayed economic data arrived far stronger than expected. The U.S. economy posted robust...

16d ago

HII

JNJ

Jury orders Johnson & Johnson to pay over $1.5B in talc case, Reuters says

A Baltimore jury has ordered Johnson & Johnson (JNJ) and its subsidiaries to pay more than $1.5B to...

16d ago

JNJ

KVUE

Johnson & Johnson issues statement on Craft verdict, intends to appeal

Erik Haas, worldwide VP of litigation, Johnson & Johnson said: “We will immediately appeal this egregious and patently...

16d ago

JNJ

Johnson & Johnson (JNJ) Faces $1.56 Billion Blow in Asbestos Lawsuit

A Maryland jury ordered Johnson & Johnson ($JNJ) to pay about $1.56 billion to a woman who claimed...

16d ago

JNJ

KVUE

Government deals lift overhang on pharma group, says BofA

BofA says Friday’s U.S. Government deals with big pharmaceutical companies were generally in-line with prior updates and provide...

17d ago

AZN

BMY

JNJ FAQ

What was Johnson & Johnson’s price range in the past 12 months?

Johnson & Johnson lowest stock price was $140.68 and its highest was $215.19 in the past 12 months.

What is Johnson & Johnson’s market cap?

Johnson & Johnson’s market cap is $492.24B.

When is Johnson & Johnson’s upcoming earnings report date?

Johnson & Johnson’s upcoming earnings report date is Jan 21, 2026 which is in 13 days.

How were Johnson & Johnson’s earnings last quarter?

Johnson & Johnson released its earnings results on Oct 14, 2025. The company reported $2.8 earnings per share for the quarter, beating the consensus estimate of $2.757 by $0.043.

Is Johnson & Johnson overvalued?

According to Wall Street analysts Johnson & Johnson’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Johnson & Johnson pay dividends?

Johnson & Johnson pays a Quarterly dividend of $1.3 which represents an annual dividend yield of 2.5%. See more information on Johnson & Johnson dividends here

What is Johnson & Johnson’s EPS estimate?

Johnson & Johnson’s EPS estimate is 2.51.

How many shares outstanding does Johnson & Johnson have?

Johnson & Johnson has 2,409,295,200 shares outstanding.

What happened to Johnson & Johnson’s price movement after its last earnings report?

Johnson & Johnson reported an EPS of $2.8 in its last earnings report, beating expectations of $2.757. Following the earnings report the stock price went down -0.032%.

Which hedge fund is a major shareholder of Johnson & Johnson?

Currently, no hedge funds are holding shares in JNJ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Johnson & Johnson Stock Smart Score

Neutral

Fundamentals

Return on Equity

33.62%

Trailing 12-Months

Asset Growth

8.15%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Johnson & Johnson (JNJ) Earnings & Revenues

Historic Earnings Reports

JNJ Company Deck

JNJ Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

Johnson & Johnson demonstrated strong overall performance with significant growth across key segments and successful new product launches. Despite challenges from STELARA's loss of exclusivity and increased tax rates, the company's strategic focus and operational achievements suggest a positive outlook.View all JNJ earnings summaries

JNJ Sales Breakdown

64.13% Innovative Medicine

35.87% MedTech

JNJ Stock 12 Month Forecast

Average Price Target

$219.05

▲(5.64% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"139":"$139","190":"$190","241":"$241","164.5":"$164.5","215.5":"$215.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":240,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$240.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":219.05,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$219.05</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":190,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$190.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[139,164.5,190,215.5,241],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,206.95,209.4923076923077,212.03461538461536,214.57692307692307,217.11923076923077,219.66153846153844,222.20384615384614,224.74615384615385,227.28846153846155,229.83076923076922,232.37307692307692,234.9153846153846,237.4576923076923,{"y":240,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,206.95,207.88076923076923,208.81153846153845,209.7423076923077,210.6730769230769,211.60384615384615,212.5346153846154,213.4653846153846,214.39615384615385,215.3269230769231,216.2576923076923,217.18846153846155,218.11923076923077,{"y":219.05,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,206.95,205.64615384615382,204.34230769230768,203.03846153846152,201.73461538461538,200.43076923076922,199.12692307692308,197.8230769230769,196.51923076923077,195.2153846153846,193.91153846153847,192.6076923076923,191.30384615384617,{"y":190,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":140.32,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":147.63,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":161.4,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":149.89,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":151.07,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":153.29,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":153.81,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":165.06,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":176.94,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":184.88,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":187.68,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":205.34,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":206.95,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >